Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Constructing sustained-release herbicide formulations based on poly-3-hydroxybutyrate and natural materials as a degradable matrix.

Kiselev EG, Boyandin AN, Zhila NO, Prudnikova SV, Shumilova AA, Baranovskiy SV, Shishatskaya EI, Thomas S, Volova TG.

Pest Manag Sci. 2019 Nov 30. doi: 10.1002/ps.5702. [Epub ahead of print]

PMID:
31785186
2.

Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.

Kiselev E, Ravji A, Kankanala J, Xie J, Wang Z, Pommier Y.

DNA Repair (Amst). 2019 Nov 6;85:102747. doi: 10.1016/j.dnarep.2019.102747. [Epub ahead of print]

PMID:
31775111
3.

Lévy Flights and Hydrodynamic Superdiffusion on the Dirac Cone of Graphene.

Kiselev EI, Schmalian J.

Phys Rev Lett. 2019 Nov 8;123(19):195302. doi: 10.1103/PhysRevLett.123.195302.

PMID:
31765178
4.

Thermal, mechanical and biodegradation studies of biofiller based poly-3-hydroxybutyrate biocomposites.

Thomas S, Shumilova AA, Kiselev EG, Baranovsky SV, Vasiliev AD, Nemtsev IV, Kuzmin AP, Sukovatyi AG, Avinash RP, Volova TG.

Int J Biol Macromol. 2019 Nov 13. pii: S0141-8130(19)37030-8. doi: 10.1016/j.ijbiomac.2019.11.112. [Epub ahead of print]

PMID:
31733250
5.

Constructing Slow-Release Fungicide Formulations Based on Poly(3-hydroxybutyrate) and Natural Materials as a Degradable Matrix.

Volova T, Prudnikova S, Boyandin A, Zhila N, Kiselev E, Shumilova A, Baranovskiy S, Demidenko A, Shishatskaya E, Thomas S.

J Agric Food Chem. 2019 Aug 21;67(33):9220-9231. doi: 10.1021/acs.jafc.9b01634. Epub 2019 Aug 8.

PMID:
31347838
6.

Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening.

Lountos GT, Zhao XZ, Kiselev E, Tropea JE, Needle D, Pommier Y, Burke TR, Waugh DS.

Nucleic Acids Res. 2019 Nov 4;47(19):10134-10150. doi: 10.1093/nar/gkz515.

7.

Synthesis of Polyhydroxyalkanoates by Hydrogen-Oxidizing Bacteria in a Pilot Production Process.

Volova T, Kiselev E, Zhila N, Shishatskaya E.

Biomacromolecules. 2019 Sep 9;20(9):3261-3270. doi: 10.1021/acs.biomac.9b00295. Epub 2019 May 23.

PMID:
31090397
8.

Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.

Kankanala J, Ribeiro CJA, Kiselev E, Ravji A, Williams J, Xie J, Aihara H, Pommier Y, Wang Z.

J Med Chem. 2019 May 9;62(9):4669-4682. doi: 10.1021/acs.jmedchem.9b00274. Epub 2019 Apr 30.

PMID:
30998359
9.

Polyhydroxyalkanoate synthesis based on glycerol and implementation of the process under conditions of pilot production.

Volova T, Demidenko A, Kiselev E, Baranovskiy S, Shishatskaya E, Zhila N.

Appl Microbiol Biotechnol. 2019 Jan;103(1):225-237. doi: 10.1007/s00253-018-9460-0. Epub 2018 Oct 26.

PMID:
30367183
10.

Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.

Zhang XR, Wang HW, Tang WL, Zhang Y, Yang H, Hu DX, Ravji A, Marchand C, Kiselev E, Ofori-Atta K, Agama K, Pommier Y, An LK.

J Med Chem. 2018 Nov 21;61(22):9908-9930. doi: 10.1021/acs.jmedchem.8b00639. Epub 2018 Oct 31.

PMID:
30336023
11.

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence.

Zhao XZ, Métifiot M, Kiselev E, Kessl JJ, Maddali K, Marchand C, Kvaratskhelia M, Pommier Y, Burke TR Jr.

Molecules. 2018 Jul 26;23(8). pii: E1858. doi: 10.3390/molecules23081858.

12.

Out-of-Bounds Hydrodynamics in Anisotropic Dirac Fluids.

Link JM, Narozhny BN, Kiselev EI, Schmalian J.

Phys Rev Lett. 2018 May 11;120(19):196801. doi: 10.1103/PhysRevLett.120.196801.

PMID:
29799225
13.

Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3'- and 5'-phosphodiester-DNA bond cleavage.

Kiselev E, Dexheimer TS, Marchand C, Huang SN, Pommier Y.

DNA Repair (Amst). 2018 Jun - Jul;66-67:64-71. doi: 10.1016/j.dnarep.2018.05.001. Epub 2018 May 2.

PMID:
29747024
14.

Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2).

Yu LM, Hu Z, Chen Y, Ravji A, Lopez S, Plescia CB, Yu Q, Yang H, Abdelmalak M, Saha S, Agama K, Kiselev E, Marchand C, Pommier Y, An LK.

Eur J Med Chem. 2018 May 10;151:777-796. doi: 10.1016/j.ejmech.2018.04.024. Epub 2018 Apr 12.

15.

New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).

Ribeiro CJA, Kankanala J, Shi K, Kurahashi K, Kiselev E, Ravji A, Pommier Y, Aihara H, Wang Z.

Eur J Pharm Sci. 2018 Jun 15;118:67-79. doi: 10.1016/j.ejps.2018.03.021. Epub 2018 Mar 21.

16.

TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.

Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.

17.

Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.

Elsayed MSA, Su Y, Wang P, Sethi T, Agama K, Ravji A, Redon CE, Kiselev E, Horzmann KA, Freeman JL, Pommier Y, Cushman M.

J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.

PMID:
28657311
18.

Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).

Wang P, Elsayed MSA, Plescia CB, Ravji A, Redon CE, Kiselev E, Marchand C, Zeleznik O, Agama K, Pommier Y, Cushman M.

J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.

PMID:
28418653
19.

Poly(3-hydroxybutyrate)/metribuzin formulations: characterization, controlled release properties, herbicidal activity, and effect on soil microorganisms.

Volova T, Zhila N, Kiselev E, Prudnikova S, Vinogradova O, Nikolaeva E, Shumilova A, Shershneva A, Shishatskaya E.

Environ Sci Pollut Res Int. 2016 Dec;23(23):23936-23950. Epub 2016 Sep 15.

PMID:
27628924
20.

Efficacy of tebuconazole embedded in biodegradable poly-3-hydroxybutyrate to inhibit the development of Fusarium moniliforme in soil microecosystems.

Volova TG, Prudnikova SV, Zhila NO, Vinogradova ON, Shumilova AA, Nikolaeva ED, Kiselev EG, Shishatskaya EI.

Pest Manag Sci. 2017 May;73(5):925-935. doi: 10.1002/ps.4367. Epub 2016 Aug 30.

PMID:
27447847
21.

Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Métifiot M, Johnson BC, Kiselev E, Marler L, Zhao XZ, Burke TR Jr, Marchand C, Hughes SH, Pommier Y.

Nucleic Acids Res. 2016 Aug 19;44(14):6896-906. doi: 10.1093/nar/gkw592. Epub 2016 Jul 1.

22.

Constructing Slow-Release Formulations of Metribuzin Based on Degradable Poly(3-hydroxybutyrate).

Boyandin AN, Zhila NO, Kiselev EG, Volova TG.

J Agric Food Chem. 2016 Jul 20;64(28):5625-32. doi: 10.1021/acs.jafc.5b05896. Epub 2016 Jul 11.

PMID:
27356030
23.

Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.

Junker A, Balasubramanian R, Ciancetta A, Uliassi E, Kiselev E, Martiriggiano C, Trujillo K, Mtchedlidze G, Birdwell L, Brown KA, Harden TK, Jacobson KA.

J Med Chem. 2016 Jul 14;59(13):6149-68. doi: 10.1021/acs.jmedchem.6b00044. Epub 2016 Jun 22.

24.

Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2.

Marchand C, Abdelmalak M, Kankanala J, Huang SY, Kiselev E, Fesen K, Kurahashi K, Sasanuma H, Takeda S, Aihara H, Wang Z, Pommier Y.

ACS Chem Biol. 2016 Jul 15;11(7):1925-33. doi: 10.1021/acschembio.5b01047. Epub 2016 May 11.

PMID:
27128689
25.

A study of synthesis and properties of poly-3-hydroxybutyrate/diethylene glycol copolymers.

Volova T, Zhila N, Kiselev E, Shishatskaya E.

Biotechnol Prog. 2016 Jul 8;32(4):1017-28. doi: 10.1002/btpr.2267. Epub 2016 Apr 27.

PMID:
27037961
26.

Constructing herbicide metribuzin sustained-release formulations based on the natural polymer poly-3-hydroxybutyrate as a degradable matrix.

Volova TG, Zhila NO, Vinogradova ON, Nikolaeva ED, Kiselev EG, Shumilova AA, Shershneva AM, Shishatskaya EI.

J Environ Sci Health B. 2016 Feb;51(2):113-125. Epub 2015 Nov 30.

PMID:
26621217
27.

Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers.

Rivero-Buceta E, Carrero P, Casanova E, Doyagüez EG, Madrona A, Quesada E, Peréz-Pérez MJ, Mateos R, Bravo L, Mathys L, Noppen S, Kiselev E, Marchand C, Pommier Y, Liekens S, Balzarini J, Camarasa MJ, San-Félix A.

Eur J Med Chem. 2015 Dec 1;106:132-43. doi: 10.1016/j.ejmech.2015.10.027. Epub 2015 Oct 21.

PMID:
26540494
28.

Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor.

Kiselev E, Balasubramanian R, Uliassi E, Brown KA, Trujillo K, Katritch V, Hammes E, Stevens RC, Harden TK, Jacobson KA.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4733-4739. doi: 10.1016/j.bmcl.2015.08.021. Epub 2015 Aug 10.

29.

Interfacial inhibitors.

Pommier Y, Kiselev E, Marchand C.

Bioorg Med Chem Lett. 2015 Sep 15;25(18):3961-5. doi: 10.1016/j.bmcl.2015.07.032. Epub 2015 Jul 18. Review.

PMID:
26235949
30.

John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors.

Jacobson KA, Gao ZG, Paoletta S, Kiselev E, Chakraborty S, Jayasekara PS, Balasubramanian R, Tosh DK.

Comput Struct Biotechnol J. 2014 Oct 16;13:286-98. doi: 10.1016/j.csbj.2014.10.004. eCollection 2015. Review.

31.

Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.

Trujillo K, Paoletta S, Kiselev E, Jacobson KA.

Bioorg Med Chem. 2015 Jul 15;23(14):4056-64. doi: 10.1016/j.bmc.2015.03.042. Epub 2015 Mar 21.

32.

Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.

Jacobson KA, Paoletta S, Katritch V, Wu B, Gao ZG, Zhao Q, Stevens RC, Kiselev E.

Mol Pharmacol. 2015 Aug;88(2):220-30. doi: 10.1124/mol.114.095711. Epub 2015 Apr 2. Review.

33.

Two disparate ligand-binding sites in the human P2Y1 receptor.

Zhang D, Gao ZG, Zhang K, Kiselev E, Crane S, Wang J, Paoletta S, Yi C, Ma L, Zhang W, Han GW, Liu H, Cherezov V, Katritch V, Jiang H, Stevens RC, Jacobson KA, Zhao Q, Wu B.

Nature. 2015 Apr 16;520(7547):317-21. doi: 10.1038/nature14287. Epub 2015 Mar 30.

34.

Renal intercalated cells sense and mediate inflammation via the P2Y14 receptor.

Azroyan A, Cortez-Retamozo V, Bouley R, Liberman R, Ruan YC, Kiselev E, Jacobson KA, Pittet MJ, Brown D, Breton S.

PLoS One. 2015 Mar 23;10(3):e0121419. doi: 10.1371/journal.pone.0121419. eCollection 2015.

35.

Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes.

Kiselev E, Barrett MO, Katritch V, Paoletta S, Weitzer CD, Brown KA, Hammes E, Yin AL, Zhao Q, Stevens RC, Harden TK, Jacobson KA.

ACS Chem Biol. 2014 Dec 19;9(12):2833-42. doi: 10.1021/cb500614p. Epub 2014 Oct 20.

36.

Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor.

Gao ZG, Balasubramanian R, Kiselev E, Wei Q, Jacobson KA.

Biochem Pharmacol. 2014 Aug 1;90(3):297-306. doi: 10.1016/j.bcp.2014.05.008. Epub 2014 May 20.

37.

Structure of the human P2Y12 receptor in complex with an antithrombotic drug.

Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E, Lu W, Fenalti G, Zhang W, Müller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q.

Nature. 2014 May 1;509(7498):115-8. doi: 10.1038/nature13083. Epub 2014 Mar 23.

38.

A glucose-utilizing strain, Cupriavidus euthrophus B-10646: growth kinetics, characterization and synthesis of multicomponent PHAs.

Volova T, Kiselev E, Vinogradova O, Nikolaeva E, Chistyakov A, Sukovatiy A, Shishatskaya E.

PLoS One. 2014 Feb 24;9(2):e87551. doi: 10.1371/journal.pone.0087551. eCollection 2014.

39.

Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.

Kiselev E, Sooryakumar D, Agama K, Cushman M, Pommier Y.

J Med Chem. 2014 Feb 27;57(4):1289-98. doi: 10.1021/jm401471v. Epub 2014 Feb 6.

40.

Cell growth and accumulation of polyhydroxyalkanoates from CO2 and H2 of a hydrogen-oxidizing bacterium, Cupriavidus eutrophus B-10646.

Volova TG, Kiselev EG, Shishatskaya EI, Zhila NO, Boyandin AN, Syrvacheva DA, Vinogradova ON, Kalacheva GS, Vasiliev AD, Peterson IV.

Bioresour Technol. 2013 Oct;146:215-222. doi: 10.1016/j.biortech.2013.07.070. Epub 2013 Jul 20.

PMID:
23934338
41.

Dibenzo[c,h][1,5]naphthyridinediones as topoisomerase I inhibitors: design, synthesis, and biological evaluation.

Kiselev E, Empey N, Agama K, Pommier Y, Cushman M.

J Org Chem. 2012 Jun 1;77(11):5167-72. doi: 10.1021/jo3006039. Epub 2012 May 15.

42.

Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.

Kiselev E, Agama K, Pommier Y, Cushman M.

J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.

43.
44.

An unexpected synthesis of 3,5-diaryl-1,2,4-thiadiazoles from thiobenzamides and methyl bromocyanoacetate.

Mayhoub AS, Kiselev E, Cushman M.

Tetrahedron Lett. 2011 Sep 21;52(38):4941-4943.

45.

7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Kiselev E, DeGuire S, Morrell A, Agama K, Dexheimer TS, Pommier Y, Cushman M.

J Med Chem. 2011 Sep 8;54(17):6106-16. doi: 10.1021/jm200719v. Epub 2011 Aug 8.

46.

Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells.

Park EJ, Kondratyuk TP, Morrell A, Kiselev E, Conda-Sheridan M, Cushman M, Ahn S, Choi Y, White JJ, van Breemen RB, Pezzuto JM.

Cancer Prev Res (Phila). 2011 Apr;4(4):592-607. doi: 10.1158/1940-6207.CAPR-10-0004.

47.

Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Kiselev E, Dexheimer TS, Pommier Y, Cushman M.

J Med Chem. 2010 Dec 23;53(24):8716-26. doi: 10.1021/jm101048k. Epub 2010 Nov 23.

48.

[Critical bone defects elimination by bioengineering construction upon non-resorbable polymeric base with the use of autogenic multipotent stromal cells from adipose tissue].

Kulakov AA, Grigor'ian AS, Kiselev EV, Khamraev TK, Filonov MR, Gatiev AB.

Stomatologiia (Mosk). 2010;89(3):9-12. Russian.

PMID:
20559227
49.

[Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].

Kiselev EN, Korytova LI, Karelin MI.

Vopr Onkol. 2005;51(6):689-91. Russian.

PMID:
17037036
50.

[Quality of life in prostatic cancer].

Kiselev EN, Karelin MI, Aleksandrov VP.

Urologiia. 2006 May-Jun;(3):88, 90-2. Review. Russian. No abstract available.

PMID:
16889101

Supplemental Content

Loading ...
Support Center